In the anammox process treating low-strength municipal wastewater, the effect of common seasonal temperature variation (15.1 °C-22.2 °C) on performance was studied. In autumn and winter, the nitrogen removal rate (NRR) decrement of 0.038kgN/(m3·d) (17.9 °C → 15.1 °C) was nearly threefold higher than 0.014kgN/(m3·d) (22.2 °C → 17.9 °C), which showed that lower temperature laid more negative impact on nitrogen removal. 15N isotope tracing tests confirmed that the contribution of denitrification to nitrogen removal was far less than anammox, and anammox contributed more at 15.1 °C (91.7%) than 21.9 °C (78.9%). Anammox bacteria could adapt to lower temperature after short-term acclimatization, especially the dominant genus Ca. Brocadia increased from 1.8% to 2.5% and its abundance was significantly correlated with nitrogen consumption (p less then 0.05). Above findings suggest that the adaptability of Ca. Brocadia could provide the possibility to maintain nitrogen removal performance at lower temperature. In spring, the improved maximum anammox activity from 2.85 to 3.23mgNH4+-N/(gVSS·h) indicated the recovered removal capacity.The anaerobic co-digestion (AcoD) of FWs produces variable methane yields, mainly due to variable carbon/nitrogen (C/N) ratio and proportions of lipids (L), carbohydrates (C), and proteins (P) in different FW samples. In this study, a significant interaction between C/N ratio and LCP composition was found and contributed to the differing trends between special (SMP) and theoretical methane production. The highest SMP of 595 mL CH4 gVS-1 occurred at C/N of 25 and LCP of 63.2522.6214.13, followed by 592 mL CH4 gVS-1 at C/N of 30 and LCP of 48.9439.7411.32, which also reflected their interaction. Attributing to their interactive effect on obtaining optimal process parameters and microbial community, the inhibition threshold of lipid as well as the methane yield was increased. Understanding the interaction between C/N ratio and LCP composition is an effective and promising way to obtain suitable mixture ratios of organic wastes under AcoD.The present study focuses on the use of microwave irradiation to improve the production of lipid, exopolysaccharide and biomass in the microalgae Scenedesmus sp. Microwave treatment conditions such as microwave power, duty cycle % and time was optimized to increase the biomass and lipid content of Scenedesmus sp. Microwave power 100 W, duty cycle 40 %, and 2 min treatment time led to a substantial improvement in the biomass and lipid content. Due to the simultaneous improvement in both the biomass and lipid content, the total lipid production was improved from 0.76 (microwave untreated) to 1.42 g/L (microwave treated) (12 days grown cells). In addition, with biomass and lipid content, microwave treatment also enhanced the production of Exopolysaccharides (EPS) up to 2.3-folds. Furthermore, biodiesel properties were improved to some extent after the microwave treatment. Microwave irradiation is a promising physical treatment method for microalgae to improve total lipid production.Switchable solvent N, N, N’, N’-tetraethyl-1,3-propanediamine (TEPDA) was proposed to extract lipids from wet Nannochloropsis oceanica with a 5% higher extraction efficiency than chloroform-methanol. It was found that TEPDA acted mainly as an organic solvent to soften and dissolve lipids, while a small amount of TEPDA was dissociated into tertiary amine ion, i.e.,(C2H5)2N-(CH2)3-NH+(C2H5)2. This cation acted as a surfactant to promote cell disruption and lipid separation. With moisture increasing from 0 to 84 wt%, more TEPDA was dissociated into cationic surfactant to induce local rearrangement of phospholipid bilayers in cell membranes through electrostatic interaction, resulting in the fractal dimension of disrupted cells increased from 1.49 to 1.66. Accordingly, the yield of fatty acid methyl ester (FAME) through transesterification of lipids extracted with TEPDA increased by 9%, while FAME yield from lipids extracted with chloroform and n-hexane decreased by 41% and 65%, respectively.Background High-throughput assays for the SARS-CoV-2 virus are critical to increasing test capacity and slowing the spread of COVID-19. Abbott Molecular developed and received emergency use authorization (EUA) to deploy the new RealTime SARS-CoV-2 assay, run on the automated m2000sp/rt system. Objective To evaluate analytical and clinical performance of the RealTime SARS-CoV-2 assay compared to the SARS-CoV-2 CDC-based laboratory developed test (LDT) in clinical use by the University of Washington Clinical Virology Laboratory (UW Virology). Methods RealTime SARS-CoV-2 assay limit of detection (LOD) was evaluated by testing two dilution panels of 60 replicates each. Cross-reactivity was evaluated by testing 24 clinical samples positive for various non‒SARS-CoV-2 respiratory viruses. Clinical performance was evaluated using 30 positive and 30 negative SARS-CoV-2 clinical samples previously tested using the UW Virology SARS-CoV-2 LDT. Results Exceeding the 100 copies/mL LOD reported in the RealTime SARS-CoV-2 assay EUA product insert, 19 of 20 replicates were detected at 50 copies/mL and 16 of 20 replicates were detected at 25 copies/mL. All clinical samples positive for 24 non‒SARS-CoV-2 respiratory viruses were SARS-CoV-2 negative on the RealTime SARS-CoV-2 assay. The assay had high sensitivity (93%) and specificity (100%) for detecting SARS-CoV-2 in clinical samples. Two positive samples that tested negative with the RealTime SARS-CoV-2 assay had cycle numbers of 35.94 or greater and required dilution prior to testing. One of these samples was also inconclusive on the SARS-CoV-2 LDT. Conclusion The RealTime SARS-CoV-2 assay is acceptable for clinical use. With the high-throughput, fully automated m2000 system, this assay will accelerate the pace of SARS-CoV-2 testing.Objectives SARS-CoV-2 infection diagnosis is challenging in patients from 2 to 3 weeks after the onset of symptoms, due to the low positivity rate of the PCR. Serologic tests could be complementary to PCR in these situations. The aim of our study was to analyze the diagnostic performance of one serologic rapid test in COVID-19 patients. Methods We evaluated a lateral flow immunoassay (AllTest COVID-19 IgG/IgM) which detects IgG and IgM antibodies. We validated the serologic test using serum samples from 100 negative patients (group 1) and 90 patients with COVID-19 confirmed by PCR (group 2). Then, we prospectively evaluated the test in 61 patients with clinical diagnosis of pneumonia of unknown etiology that were negative for SARS-CoV-2 by PCR (group 3). Results All 100 patients from group 1 were negative for the serologic test (specificity = 100 %). find more Regarding group 2 (PCR-positive), the median time from their symptom onset until testing was 17 days. For these 90 group-2 patients, the test was positive for either IgM or IgG in 58 (overall sensitivity = 64.